ABSTRACT BACKGROUND Sleep apnea is common in hospitalized heart failure (HF) patients and is associated with increased
S
leep apnea is more common in patients with heart failure (HF) than in the general population, with a reported prevalence of 50% to 75% (1, 2) . There are 2 main types of sleep apnea: obstructive (OSA) and central (CSA). OSA is common in patients with HF with preserved ejection fraction (HFpEF), with a prevalence of 69% to 81% (3, 4) , and is independently associated with a worse prognosis (5) , even when HF therapy is optimal (6) . As cardiac function worsens, CSA and Cheyne-Stokes respiration increase in severity (1, 3) , with apnea-hypopnea index (AHI) >30/h in many patients with acute decompensation of HF (7, 8) . CSA worsening might be due to stimulation of stretch J-receptors by pulmonary congestion, which promotes hyperventilation and respiratory instability (9) . The presence of CSA during HF admission is associated with an increased risk of morbidity and mortality including higher rates of HF rehospitalization (10, 11) , and often persists after successful management of the acute decompensation episode (8, 12, 13) .
Noninvasive positive airway pressure therapy with adaptive servo-ventilation (ASV) is indicated for treatment of both CSA and OSA, and is more effective and better tolerated than continuous positive airway pressure when treating CSA in HF patients (14, 15) .
The results of several small studies and metaanalyses showed ASV improved plasma B-type natriuretic peptide (BNP) concentration, left ventricular ejection fraction (LVEF), quality of life (QOL), functional outcomes, and mortality in patients with heart failure with reduced ejection fraction (HFrEF) and CSA (16) (17) (18) (19) (20) . Conversely, the SERVE-HF (Adaptive
Servo-Ventilation for Central Sleep Apnea in Systolic
Heart Failure) trial, the first large randomized trial of ASV in chronic stable HFrEF patients with predominant CSA, was neutral for the primary composite endpoint. There was a signal for increased mortality, especially cardiovascular (CV) death, in patients randomized to ASV, particularly in the subgroup of patients who had worse left ventricular function (21, 22) .
There are currently no data from large randomized trials on the effects of positive airway pressure therapy for sleep apnea in patients hospitalized for HF.
However, observational data suggest that treating sleep apnea in the post-acute setting might reduce mortality risk (11) . The CAT-HF (Cardiovascular Improvements With MV-ASV Therapy in Heart Failure) study investigated whether treatment of hospitalized HF patients with moderate-to-severe sleep apnea with ASV in addition to optimized medical therapy (OMT) was associated with improved 6-month cardiovascular outcomes compared with OMT alone (control).
METHODS
The CAT-HF study was a randomized, controlled, multicenter clinical trial. The study design has been reported previously (23) . In brief, hospitalized HF patients with either reduced or preserved ejection fraction and an AHI $15 events per h were randomized to usual care or active treatment in a 1:1 ratio.
Two-hundred fifteen patients were intended to be Flow of patients through the CAT-HF (Cardiovascular Improvements With MV-ASV Therapy in Heart Failure) study. *Subjects who withdrew consent or were lost to follow-up were included in the global rank endpoint analysis up to the point that they left the study. AHI ¼ apneahypopnea index; ASV ¼ adaptive servo-ventilation; HF ¼ heart failure; PAP ¼ positive airway pressure.
Registry). Randomization was stratified by LVEF as
HFpEF (EF >45%) or HFrEF (EF #45%) and site using a permuted block design.
ENDPOINTS. The primary endpoint was a composite global rank endpoint (26), which evaluates a rank order response (26) SAMPLE SIZE. The primary analysis was based on the Wilcoxon-Mann-Whitney test, and therefore, the power calculation was approximated using the approach of Tang (27) . Hypothesized differences between treatment groups were grouped across 5 categories.
The hypothesized death or CV hospitalization differences were 25% for ASV versus 35% for control, and the hypothesized difference between groups in the percentage event free with a 6MWD improvement were 40% for ASV versus 20% for control. Assuming a 2-sided type I error of 0.05, the hypothesized differences provide 80% power with a sample size of 200 subjects. We planned to randomize a total of 215 subjects to achieve 200 evaluable subjects (100 per arm). Values are mean AE SD, median (interquartile range), n (%), or n/N (%). *p > 0.05 for all comparisons between ASV and control groups.
6MWD ¼ 6-min walk distance; ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ASV ¼ adaptive servo-ventilation; COPD ¼ chronic obstructive pulmonary disease; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; ICD ¼ implantable cardioverter-defibrillator; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal B-type natriuretic peptide; NYHA ¼ New York Heart Association.
The primary analysis of the global rank endpoint was conducted using the Wilcoxon test. As a secondary analysis, and to support graphical presentation, a Cox proportional hazards model was used to test the significance of differences between the ASV and control groups overall for both pre-specified subgroups and interaction tests. Overall, the median patient age was 62 years, 26%
were women, and 41% were Black. The majority of patients (n ¼ 102; 81%) had HFrEF and 24 (19%) had HFpEF; 41% of patients had atrial fibrillation at baseline. There were no statistically significant differences in baseline characteristics between the control and ASV groups (Tables 1 and 2 ).
In the ASV group, the average device usage at 
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Change in mean AHI over time in the ASV and control groups. events/h ¼ events per hour; other abbreviations as in Figure 1 .
Cardiovascular Effects of Adaptive Servo-Ventilation in HF significant differences between the ASV and control groups ( Figure 3) .
In the mITT analysis, the global rank endpoint This trial considered whether adaptive servo-ventilation (ASV) improved cardiovascular (CV) outcomes in hospitalized heart failure (HF) patients with moderate-tosevere sleep apnea. The primary endpoint was a composite global rank score of hierarchy of death, CV hospitalizations, and change in 6-min walk distance (6MWD) at 6 months in patients randomized to ASV plus optimized medical therapy or optimized medical therapy alone (control). There was no significant difference in the primary endpoint, although pre-specified subgroup analysis suggested a positive effect of ASV in patients with HF with preserved ejection fracture (HFpEF). 6MWD
Better implies 6-month event-free survival and an improvement from baseline in 6MWD >50%; 6MWD Worse implies 6-month event-free survival and a decrease from baseline in 6MWD or missing 6MWD at 6 months. HFrEF ¼ heart failure with reduced ejection fraction. 
Death at 6 months 4 (6) 7 (11) 3 (6) 7 (14) 1 (8) 0 (0) CV hospitalization (excluding deaths) 24 (37) 17 (28) 22 (42) 12 (24) 2 (15) 5 (45) 6MWD worse* 12 (18) 13 (21) 9 (17) 9 (18) 3 (23) 4 (36) 6MWD same* 18 (28) 13 (21) 12 (23) 11 (22) 6 (46) 2 (18) 6MWD better* 7 (11) 11 (18) 6 (12) 11 (22) 1 (8) Values are n (%). Subjects were classified as "Worse" if the 6MWD at 6 months had decreased from baseline; subjects alive without CV hospitalization and missing 6MWD were classified as 6MWD Worse. Subjects were classified as Same if the 6MWD at 6 months was better than baseline by no >50%. Subjects were classified as Better if the 6MWD increased by >50% from baseline to 6 months. *For the subset of patients alive and without cardiovascular hospitalization at 6 months.
6MWD ¼ 6-min walk distance; CV ¼ cardiovascular; HFpEF ¼ heart failure with preserved ejection fraction; other abbreviations as in Table 1 . are shown for all patients, patients with heart failure with reduced ejection fraction (HFrEF), and patients with heart failure with preserved ejection fraction (HFpEF).
6MWD Better implies 6-month event-free survival and an improvement from baseline in 6MWD of >50%. 6MWD Worse implies 6-month event-free survival and a decrease from baseline in 6MWD or missing 6MWD at 6 months. Afib ¼ atrial fibrillation; BMI ¼ body mass index; CI ¼ confidence interval; EF ¼ ejection fraction; HR ¼ hazard ratio; other abbreviations as in Figure 1 .
(Kansas City Cardiomyopathy Questionnaire score) ( Table 4) . Changes in NYHA functional class during the study were not markedly different in the 2 groups (Online Table 1 ). (21), and that the response to ASV might be different in those with a higher ejection fraction.
DISCUSSION
Although preliminary, the pre-specified subgroup analysis results from CAT-HF deserve further investigation given the differing presentations and epidemiology of HFpEF and HFrEF (37, 38) , the fact that there have been no improvements in survival for
HFpEF patients over time (39) , and that there are currently no evidence-based effective therapies for
HFpEF, means that the focus is primarily on Values are mean AE SD, median (interquartile range), or n (%). *Complete case analysis based on the subset with 6-month 6MWD. †In patients with reduced EF. ‡In patients with preserved EF.
DASI ¼ Duke Activity Status Index; EQ-5D-5L ¼ EuroQol-5D-5L; EF ¼ ejection fraction; hs-CRP ¼ highsensitivity C-reactive protein; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LVESVI ¼ left ventricular end-systolic volume index; ODI ¼ oxygen desaturation index; PHQ-9 ¼ Patient Health Questionnaire-9; PSQI ¼ Pittsburgh Sleep Quality Index; other abbreviations as in Tables 1 and 2. 
